ASLAN Pharmaceuticals Announces IND Submission for ASLAN003 to U.S. FDA and Conclusion of 30-Day Review Period
January 04, 2019 02:00 ET
|
ASLAN Pharmaceuticals Limited
- ASLAN003 is an orally active, potent inhibitor of DHODH that has the potential to be first-in-class in AML- Positive interim Phase 2a data for ASLAN003 in AML was presented at the 2018 ASH Annual...
TLC Reports Last Patient Last Visit (LPLV) in TLC599 Phase II Trial and FDA Clearance to Commence New Clinical Trials
July 09, 2018 15:01 ET
|
Taiwan Liposome Company, Ltd.
LPLV marks the final steps toward completion of TLC599 trial for osteoarthritis (OA) painPhase II topline results on-track for 2018 releaseSet to initiate enrollment of US Phase II pharmacokinetic...
Voyager Therapeutics Announces FDA Clearance of Investigational New Drug Application for VY-AADC for Advanced Parkinson’s Disease
January 23, 2018 07:04 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
aTyr Pharma Announces Poster Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium
December 21, 2017 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Dec. 21, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat...
Orphazyme assumes sponsorship of Phase II/III sIBM trial
December 15, 2017 09:20 ET
|
ORPHAZYME A/S
Investor newsNo. 01/2017 Orphazyme assumes sponsorship of Phase II/III sIBM trial On December 14, 2017, Orphazyme A/S, University of Kansas Medical Center, and UCL announced that Orphazyme...
AXIM Biotech Announces Successful Completion of Pre-IND Meeting with FDA on Comparable Product to Marinol; Green Light from FDA for IND Submission
December 12, 2017 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Dec. 12, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC:AXIM), a world leader in cannabinoid research and development, announced today that it has successfully completed a...
2X Oncology Obtains Investigational New Drug Application for 2X-111 Glutathione Enhanced PEGylated Liposomal Doxorubicin
June 08, 2017 09:06 ET
|
2X Oncology, Inc.
CAMBRIDGE, Mass., June 08, 2017 (GLOBE NEWSWIRE) -- 2X Oncology, Inc. ("2X" or the "Company"), a precision medicine company developing targeted therapeutics to address significant unmet needs in...
TESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to the U.S. FDA
May 01, 2017 08:30 ET
|
TESARO, Inc.
WALTHAM, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the submission of an Investigational New Drug (IND)...
Akari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNH
January 03, 2017 07:00 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug...
Axsome Therapeutics Receives FDA Clearance of IND for Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation
January 03, 2017 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...